KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Petmed Express (PETS) over the last 16 years, with Q4 2025 value amounting to $2.4 million.

  • Petmed Express' Depreciation & Amortization (CF) rose 5126.1% to $2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.0 million, marking a year-over-year increase of 3169.1%. This contributed to the annual value of $7.0 million for FY2025, which is 24.09% down from last year.
  • Latest data reveals that Petmed Express reported Depreciation & Amortization (CF) of $2.4 million as of Q4 2025, which was up 5126.1% from $2.3 million recorded in Q3 2025.
  • Petmed Express' Depreciation & Amortization (CF)'s 5-year high stood at $2.4 million during Q4 2025, with a 5-year trough of $636000.0 in Q1 2021.
  • For the 5-year period, Petmed Express' Depreciation & Amortization (CF) averaged around $1.4 million, with its median value being $1.6 million (2024).
  • As far as peak fluctuations go, Petmed Express' Depreciation & Amortization (CF) soared by 12284.2% in 2023, and later crashed by 1039.55% in 2024.
  • Petmed Express' Depreciation & Amortization (CF) (Quarter) stood at $710000.0 in 2021, then soared by 32.54% to $941000.0 in 2022, then surged by 88.1% to $1.8 million in 2023, then dropped by 10.4% to $1.6 million in 2024, then soared by 51.26% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q4 2025, $2.3 million for Q3 2025, and $2.3 million during Q2 2025.